Sanofi & GSK to support COVAX with 200 m adjuvanted recombinant protein-based COVID-19 vaccines
Sanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read moreSanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read moreEli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read moreThe Janssen Pharmaceutical Companies of Johnson & Johnson revealed on Monday the submission of the supplemental New Drug Application (sNDA)
Read moreAstraZeneca has confirmed that the U.S. FDA has authorised the resumption of Phase III clinical trials of the COVID-19 AZD1222
Read morePhenomic AI, a Canadian biotechnology company that uses an AI/ML platform for targeting the tumor stroma, has launched with $6
Read moreRoche revealed on Monday that Venclexta ® (venetoclax) in conjunction with azacitidine or decitabine or low-dose cytarabine (LDAC) has been
Read moreEli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreViiV Healthcare’s GEMINI studies showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine, appeared to have non-inferior potency in
Read moreUK clinicians are being advised to “think carefully” before ordering tests as pharma group Roche is experiencing logistical challenges due
Read moreBristol Myers Squibb is strengthening its cardiovascular pipeline through a $13.1 Billion acquisition of biotech firm MyoKardia. The $13.1 Billion
Read more